A brief communication: Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: Linking autoimmunity and atherosclerosis

Experimental Biology and Medicine

Volumn 234, Issue 3, 2009, Pages 354-360

  Reiss, Allison B ^a   Wan, David W ^a,b   Anwar, Kamran ^a   Merrill, Joan T ^c   Wirkowski, Peter A ^a   Shah, Nidhi ^a   Cronstein, Bruce N ^b   Chan, Edwin S L ^b   Carsons, Steven E ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Atherosclerosis; CD36; Cholesterol; Lupus erythematosus; Macrophage scavenger receptor; Systemic

Indexed keywords

CD36 ANTIGEN; MESSENGER RNA;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNITY; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MONOCYTE; MYELOID LEUKEMIA; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; BLOOD; CASE CONTROL STUDY; CELL LINE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MALE; METABOLISM;

ADULT; ANTIGENS, CD36; ATHEROSCLEROSIS; AUTOIMMUNITY; CASE-CONTROL STUDIES; CELL LINE; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MONOCYTES; RNA, MESSENGER;

EID: 63349094507     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0806-BC-194     Document Type: Article

References (34)

1. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2407-2415, 2003.[Abstract/Free Full Text]
2. Hahn B, McMahon M. Atherosclerosis and systemic lupus erythematosus: the role of altered lipids and of autoantibodies. Lupus 17:368-370, 2008. [Abstract/Free Full Text]
3. Frostegard J. Systemic lupus erythematosus and cardiovascular disease. Lupus 17:364-367, 2008. [Abstract/Free Full Text]
4. Esdaile JM, Panaritis C, Abrahamowicz M. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44:2331-2337, 2001.[CrossRef][Medline]
5. McMahon M, Hahn B. Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol 19: 633-639, 2007.[CrossRef][Medline]
6. de Carvalho JF, Bonfa E, Borba EF. Systemic lupus erythematosus and "lupus dyslipoproteinemia." Autoimmun Rev 7:246-250, 2008.[CrossRef][Medline]
7. Delgado-Alves J, Ames PRJ. Atherosclerosis, oxidative stress and autoantibodies in systemic lupus erythematosus and primary anti-phospholipid syndrome. Immunobiology 207:23-28, 2003. [CrossRef][Medline]
8. Nicholson AC, Pearce SFA, Silverstein RL. Oxidized LDL binds to CD36 on human monocytederived macrophages and transfected cell lines. Evidence implicating the lipid moiety of the lipoprotein as the binding site. Arterioscler Thromb Vasc Biol 15:269-275, 1995. [Abstract/Free Full Text]
9. Reiss AB, Merrill JT, Rahman MM, Hasneen K, Chan ESL, Belmont HM, Khoa ND, Cronstein BN. Inhibition of expression of the anti-atherogenic cholesterol 27-hydroxylase in human monocytoid cells exposed to SLE patient serum is abrogated by blocking the interferon-gamma receptor. Arthritis Rheum 48:S196, 2003.
10. Matsuura E, Kobayashi K, Hurley BL, Lopez LR. Atherogenic oxidized low-density lipoprotein/beta2-glycoprotein I (oxLDL/beta2G-PI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 15:478-483, 2006.[Abstract/Free Full Text]
11. Gerasimova EV, Alekberova ZS, Popkova TV, Sobenin IA. Atherogenic cholesterol-containing circulating immune complexes-one of the components of the serum in patients with systemic lupus erythematosus. Klin Med (Mosk) 81:39-41, 2003.
12. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-1277, 1982.[Medline]
13. Han S, Sidell N. Peroxisome-proliferator-activated-receptor gamma (PPARgamma) independent induction of CD36 in THP-1 monocytes by retinoic acid. Immunology 106:53-59, 2002. [CrossRef][Medline]
14. Reiss AB, Patel CA, Rahman MM, Chan ES, Hasneen K, Montesinos MC, Trachman JD, Cronstein BN. Interferon-gamma impedes reverse cholesterol transport and promotes foam cell transformation in THP-1 human monocytes/macrophages. Med Sci Monit 10:BR420-425, 2004. [Medline]
15. Rahman EU, Ruan XZ, Chana RS, Brunskill NJ, Powis SH, Varghese Z, Moorhead JF, Wheeler DC. Mesangial matrix-activated monocytes express functional scavenger receptors and accumulate intracellular lipid. Nephrol Dial Transplant 23:1876-1885, 2008. [Abstract/Free Full Text]
16. Kotzin BL. Systemic lupus erythematosus. Cell 85:303-306, 1996.[CrossRef][Medline]
17. Reid HL, De Ceulaer K. Abnormal plasma and serum viscosity in systemic lupus erythematosus (SLE): a Jamaican study. Clin Hemorheol Microcirc 20:175-180, 1999.[Medline]
18. Cottiero RA, Madaio MP, Levey AS. Glomerular filtration rate and urinary albumin excretion rate in systemic lupus erythematosus. Nephron 69:140-146, 1995.[Medline]
19. Kim YG. Serum cholesterol in idiopathic and lupus-related protein-losing enteropathy. Lupus 17:575-579, 2008.[Abstract/Free Full Text]
20. Nicholson AC, Han J, Febbraio M, Silverstein RL, Hajjar DP. Role of CD36, the macrophage class B scavenger receptor, in atherosclerosis. Ann N Y Acad Sci 947:224-228, 2001.[CrossRef] [Medline]
21. Collot-Teixeira S, Martin J, McDermott-Roe C, Poston R, McGregor JL. CD36 and macrophages in atherosclerosis. Cardiovasc Res 75:468-477, 2007.[Abstract/Free Full Text]
22. Nozaki S, Kashiwagi H, Yamashita S, Nakagawa T, Kostner B, Tomiyama Y, Nakata A, Ishigamia M, Miyagawa J, Kameda-Takemura K, Kurata Y, Matsuzawa Y. Reduced uptake of oxidized low density lipoprotein in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest 96:1859-1865, 1995.[Medline]
23. Nakata A, Nakagawa Y, Nishida M, Nozaki S, Miyagawa J, Nakagawa T, Tamura R, Matsumoto K, Kameda-Takemura K, Yamashita S, Matsuzawa Y. CD36, a novel receptor for oxidized lowdensity lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta. Arterioscler Thromb Vasc Biol 19:1333-1339, 1999.[Abstract/Free Full Text]
24. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105:1049-1056, 2000.[Medline]
25. Febbraio M, Guy E, Silverstein RL. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler Thromb Vasc Biol 24:2333-2338, 2004. [Abstract/Free Full Text]
26. Kuchibhotla S, Vanegas D, Kennedy DJ, Guy E, Nimako G, Morton RE, Febbraio M. Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II. Cardiovasc Res 78:185-196, 2008. [Abstract/Free Full Text]
27. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF, Freeman MW. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 277:49982-49988, 2002.[Abstract/Free Full Text]
28. Bottcher A, Gaipl US, Furnrohr BG, Herrmann M, Girkontaite I, Kalden JR, Voll RE. Involvement of phosphatidylserine, alphavbeta3, CD14, CD36, and complement C1q in the phagocytosis of primary necrotic lymphocytes by macrophages. Arthritis Rheum 54:927-938, 2006.[CrossRef][Medline]
29. Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol 1:297-329, 2006.[CrossRef][Medline]
30. Hofnagel O, Luechtenborg B, Weissen-Plenz G, Robenek H. Statins and foam cell formation: impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors. Biochim Biophys Acta 1771:1117-1124, 2007.[Medline]
31. Bassi N, Ghirardello A, Iaccarino L, Zampieri S, Rampudda ME, Atzeni F, Sarzi-Puttini P, Shoenfeld Y, Doria A. OxLDL/beta2GPI-anti-oxLDL/beta2GPI complex and atherosclerosis in SLE patients. Autoimmun Rev 7:52-58, 2007.[CrossRef][Medline]
32. Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, Gilburd B, Corbanese S, Patnaik M, Zampieri S, Peter JB, Favaretto E, Iaccarino L, Sherer Y, Todesco S, Pauletto P. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 62:1071-1077, 2003.[Abstract/Free Full Text]
33. George J, Afek A, Gilburd B, Harats D, Shoenfeld Y. Autoimmunity in atherosclerosis: lessons from experimental models. Lupus 9:223-227, 2000.[Abstract/Free Full Text]
34. Nagarajan S. Anti-OxLDL IgG blocks OxLDL interaction with CD36, but promotes FcgammaR, CD32A-dependent inflammatory cell adhesion. Immunol Lett 108:52-61, 2007.[CrossRef] [Medline]